Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 6/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075594 | 0.91 | RORC (0.45) | RORCFAAHCNR1CNR2EPHX2 | |
| SCHEMBL5821503 | 0.89 | FAAH (0.37) | FAAHCNR1CNR2RBP4 | |
| SCHEMBL4087335 | 0.87 | HTT (0.44) | RORCFAAHCNR1CNR2MAPT | |
| SCHEMBL4079472 | 0.86 | RORC (0.38) | RORCFAAHCNR1CNR2RBP4 | |
| SCHEMBL29575942 | 0.85 | CNR1 (0.48) | FAAHCNR1RBP4 | |
| SCHEMBL4089340 | 0.85 | CNR1 (0.48) | FAAHCNR1RBP4 | |
| SCHEMBL4075844 | 0.84 | CNR1 (0.40) | FAAHCNR1CNR2RBP4 | |
| SCHEMBL4079999 | 0.82 | CNR1 (0.51) | FAAHCNR1CNR2 | |
| SCHEMBL29574930 | 0.82 | CNR1 (0.51) | FAAHCNR1CNR2 | |
| SCHEMBL4075602 | 0.81 | EPHX2 (0.40) | CNR1CNR2EPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | claimed |
| US-7504522-B2 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMITED (GB) | 2009-03-17 | — | — | US | claimed |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMAITED (GB) | 2007-03-08 | — | — | US | claimed |
| EP-1620395-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-02-01 | — | — | EP | claimed |
| WO-2004096763-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | claimed |
| US-20240000748-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2022109043-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220151990-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220151990-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | ANEBULO PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | ANEBULO PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-7504522-B2 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMAITED (GB) | 2007-03-08 | — | — | US | disclosed |
| EP-1620395-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096763-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | CNR1, CNR2, GPR119 | RORC 875/4885FAAH 8/4885CNR1 1/4885 |
| US-20240000748-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | CNR1, CNR2, FAAH | RORC 1677/4885FAAH 3/4885CNR1 1/4885 |
| US-20220151990-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | CNR1, CNR2, FAAH | RORC 1677/4885FAAH 3/4885CNR1 1/4885 |
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | CNR1, CNR2, FAAH | RORC 1677/4885FAAH 3/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.